Corbus's lead drug succeeds in mid-stage scleroderma study

(Reuters) - Corbus Pharmaceuticals Holdings Inc said its lead drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable autoimmune condition caused by abnormal growth of connective tissue.